7 research outputs found
Diseño de organizaciones virtuales ubícuas utilizando desarrollo dirigido por modelos
Hoy en día los avances en la miniaturización de sistemas electrónicos han
impulsado el desarrollo de dispositivos o artefactos que incorporan capacidades
computacionales y de comunicación. Estos dispositivos pueden proveer de
una serie de servicios en diferentes entornos gracias a su tecnología empotrada,
como por ejemplo: reconocimiento de personas, localización de usuarios en un
entorno, ajuste automático de la temperatura e iluminación de un entorno, etc.
Este potencial de procesamiento y comunicación, está permitiendo crear nuevas
aplicaciones distribuidas, donde el rol principal no lo tiene el computador personal,
sino los diferentes dispositivos empotrados en el entorno: sensores, interfaces,
actuadores, teléfonos móviles, etc., Esto ha generado novedosas áreas de aplicación
como: Internet de Cosas (Internet of Things), Computación Móvil, Redes
de Sensores, Sistemas Ubícuos, Inteligencia Ambiental, etc.
Estos avances han conducido al desarrollo de un nuevo paradigma, computación
orientada a la interacción, es decir, la computación ocurre a través de los
actos de comunicación entre las entidades. Por lo tanto, es lógico pensar que este
paradigma requiere, desde un punto de vista de diseño, el desarrollo de aplicaciones
en diferentes plataformas de software y de hardware, debido a lo heterogeneo
de los sistemas de computación, lenguajes, sistemas operativos, y objetos (dispositivos
físicos: sensores, actuadores, interfaces, etc.) dispersos en el entorno.
Dicha heterogeneidad presente en los sistemas ubícuos, representa todo un reto
a la hora de diseñarlos.
La ingeniería de software basada en sistemas multi-agente, en particular, los
sistemas multi-agente abiertos (como las Organizaciones Virtuales), tiene la capacidad
de abordar los retos al diseñar sistemas ubícuos. A ello hay que unir, que
varias metodologías de desarrollo de software han adoptado el enfoque “dirigido
por modelos” (model-driven) para realizar el análisis y el diseño del software.
Dicho enfoque puede ser adoptado en los sistemas multi-agente, para mejorar el
proceso de desarrollo y la calidad del software basado en agentes. Así mismo, el
desarrollo dirigido por modelos proporciona un soporte apropiado para abordar
este tipo de sistemas, ya que nos permite el uso de modelos como principal elemento
abstracto para el diseño del sistema, por medio de la interconexión de un conjunto de componentes visuales.
En este trabajo proponemos el desarrollo de sistemas ubícuos utilizando una
organización virtual, creando una Organización Virtual Ubícua, la cual es diseñada
usando el enfoque de desarrollo dirigido por modelos. De forma más
detallada, este trabajo presenta tres propuestas. La primera, presenta un conjunto
de meta-modelos para diseñar una Organización Virtual Ubícua, llamado
πVOM, que utiliza conceptos generales que se abstraen de las metodologías y de
las plataformas de agentes, lo permite diseñar aplicaciones utilizando abstracciones
generales de alto nivel, evitando los detalles de implementación de bajo
nivel. Así mismo, se presentan dos modelos de transformaciones, que permiten
obtener el modelo de implantación de la organización (con los agentes, entidades
y dispositivos), por medio de transformaciones semi-automáticas dadas por la
metodología model-driven, reduciendo la brecha entre las fases de diseño y de
implementación para este tipo de sistema.
La segunda propuesta presenta una arquitectura de implantación que define
una estructura de capas funcionales basada en servicios, que soporta la interacción
de las entidades de la organización virtual. La arquitectura de implantación
permite la interoperabilidad de diferentes entidades, plataformas de software y
hardware, proporcionando a los miembros de la organización virtual la capacidad
de administrar y controlar los dispositivos del entorno (del sistema ubícuo).
La tercera propuesta presenta una plataforma de ejecución de agentes empotrados
llamada Andromeda, que permite ejecutar agentes empotrados sobre
sistema operativo Android que cumplen con el modelo de agente de πVOM. Los
agentes en Andromeda pueden acceder a los dispositivos del entorno, tal y
como sucede en los sistemas ubícuos.
Las propuestas presentadas fueron evaluadas empíricamente con dos ejemplos,
que permiten mostrar sus bondades.Aguero Medina, J. (2015). Diseño de organizaciones virtuales ubícuas utilizando desarrollo dirigido por modelos [Tesis doctoral no publicada]. Universitat Politècnica de València. https://doi.org/10.4995/Thesis/10251/52597TESI
Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world
Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic.
Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality.
Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States.
Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis.
Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection
Diseño de agentes empotrados utilizando desarrollo dirigido por modelos para plataformas móviles
Este trabajo presenta un meta-modelo de agente que usa el enfoque MDA. También se presenta un
proceso de transformación que permite obtener el código del agente sobre las plataformas ANDROMEDA y JADE-Leap, que ejecutan agentes impotrados. Finalmente, se describe la plataforma dee agente ANDROMEDA desarrollada sobre el sistema Android de Google.Aguero Medina, J. (2008). Diseño de agentes empotrados utilizando desarrollo dirigido por modelos para plataformas móviles. http://hdl.handle.net/10251/12180Archivo delegad
Recommended from our members
Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study
BackgroundMultisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory condition associated with SARS-CoV-2 infection, has emerged as a serious illness in children worldwide. Immunoglobulin or glucocorticoids, or both, are currently recommended treatments.MethodsThe Best Available Treatment Study evaluated immunomodulatory treatments for MIS-C in an international observational cohort. Analysis of the first 614 patients was previously reported. In this propensity-weighted cohort study, clinical and outcome data from children with suspected or proven MIS-C were collected onto a web-based Research Electronic Data Capture database. After excluding neonates and incomplete or duplicate records, inverse probability weighting was used to compare primary treatments with intravenous immunoglobulin, intravenous immunoglobulin plus glucocorticoids, or glucocorticoids alone, using intravenous immunoglobulin as the reference treatment. Primary outcomes were a composite of inotropic or ventilator support from the second day after treatment initiation, or death, and time to improvement on an ordinal clinical severity scale. Secondary outcomes included treatment escalation, clinical deterioration, fever, and coronary artery aneurysm occurrence and resolution. This study is registered with the ISRCTN registry, ISRCTN69546370.FindingsWe enrolled 2101 children (aged 0 months to 19 years) with clinically diagnosed MIS-C from 39 countries between June 14, 2020, and April 25, 2022, and, following exclusions, 2009 patients were included for analysis (median age 8·0 years [IQR 4·2-11·4], 1191 [59·3%] male and 818 [40·7%] female, and 825 [41·1%] White). 680 (33·8%) patients received primary treatment with intravenous immunoglobulin, 698 (34·7%) with intravenous immunoglobulin plus glucocorticoids, 487 (24·2%) with glucocorticoids alone; 59 (2·9%) patients received other combinations, including biologicals, and 85 (4·2%) patients received no immunomodulators. There were no significant differences between treatments for primary outcomes for the 1586 patients with complete baseline and outcome data that were considered for primary analysis. Adjusted odds ratios for ventilation, inotropic support, or death were 1·09 (95% CI 0·75-1·58; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids and 0·93 (0·58-1·47; corrected p value=1·00) for glucocorticoids alone, versus intravenous immunoglobulin alone. Adjusted average hazard ratios for time to improvement were 1·04 (95% CI 0·91-1·20; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids, and 0·84 (0·70-1·00; corrected p value=0·22) for glucocorticoids alone, versus intravenous immunoglobulin alone. Treatment escalation was less frequent for intravenous immunoglobulin plus glucocorticoids (OR 0·15 [95% CI 0·11-0·20]; p<0·0001) and glucocorticoids alone (0·68 [0·50-0·93]; p=0·014) versus intravenous immunoglobulin alone. Persistent fever (from day 2 onward) was less common with intravenous immunoglobulin plus glucocorticoids compared with either intravenous immunoglobulin alone (OR 0·50 [95% CI 0·38-0·67]; p<0·0001) or glucocorticoids alone (0·63 [0·45-0·88]; p=0·0058). Coronary artery aneurysm occurrence and resolution did not differ significantly between treatment groups.InterpretationRecovery rates, including occurrence and resolution of coronary artery aneurysms, were similar for primary treatment with intravenous immunoglobulin when compared to glucocorticoids or intravenous immunoglobulin plus glucocorticoids. Initial treatment with glucocorticoids appears to be a safe alternative to immunoglobulin or combined therapy, and might be advantageous in view of the cost and limited availability of intravenous immunoglobulin in many countries.FundingImperial College London, the European Union's Horizon 2020, Wellcome Trust, the Medical Research Foundation, UK National Institute for Health and Care Research, and National Institutes of Health
Reduction of cardiac imaging tests during the COVID-19 pandemic: The case of Italy. Findings from the IAEA Non-invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID)
Background: In early 2020, COVID-19 massively hit Italy, earlier and harder than any other European country. This caused a series of strict containment measures, aimed at blocking the spread of the pandemic. Healthcare delivery was also affected when resources were diverted towards care of COVID-19 patients, including intensive care wards. Aim of the study: The aim is assessing the impact of COVID-19 on cardiac imaging in Italy, compare to the Rest of Europe (RoE) and the World (RoW). Methods: A global survey was conducted in May–June 2020 worldwide, through a questionnaire distributed online. The survey covered three periods: March and April 2020, and March 2019. Data from 52 Italian centres, a subset of the 909 participating centres from 108 countries, were analyzed. Results: In Italy, volumes decreased by 67% in March 2020, compared to March 2019, as opposed to a significantly lower decrease (p < 0.001) in RoE and RoW (41% and 40%, respectively). A further decrease from March 2020 to April 2020 summed up to 76% for the North, 77% for the Centre and 86% for the South. When compared to the RoE and RoW, this further decrease from March 2020 to April 2020 in Italy was significantly less (p = 0.005), most likely reflecting the earlier effects of the containment measures in Italy, taken earlier than anywhere else in the West. Conclusions: The COVID-19 pandemic massively hit Italy and caused a disruption of healthcare services, including cardiac imaging studies. This raises concern about the medium- and long-term consequences for the high number of patients who were denied timely diagnoses and the subsequent lifesaving therapies and procedures
International Impact of COVID-19 on the Diagnosis of Heart Disease
Background: The coronavirus disease 2019 (COVID-19) pandemic has adversely affected diagnosis and treatment of noncommunicable diseases. Its effects on delivery of diagnostic care for cardiovascular disease, which remains the leading cause of death worldwide, have not been quantified. Objectives: The study sought to assess COVID-19's impact on global cardiovascular diagnostic procedural volumes and safety practices. Methods: The International Atomic Energy Agency conducted a worldwide survey assessing alterations in cardiovascular procedure volumes and safety practices resulting from COVID-19. Noninvasive and invasive cardiac testing volumes were obtained from participating sites for March and April 2020 and compared with those from March 2019. Availability of personal protective equipment and pandemic-related testing practice changes were ascertained. Results: Surveys were submitted from 909 inpatient and outpatient centers performing cardiac diagnostic procedures, in 108 countries. Procedure volumes decreased 42% from March 2019 to March 2020, and 64% from March 2019 to April 2020. Transthoracic echocardiography decreased by 59%, transesophageal echocardiography 76%, and stress tests 78%, which varied between stress modalities. Coronary angiography (invasive or computed tomography) decreased 55% (p < 0.001 for each procedure). In multivariable regression, significantly greater reduction in procedures occurred for centers in countries with lower gross domestic product. Location in a low-income and lower–middle-income country was associated with an additional 22% reduction in cardiac procedures and less availability of personal protective equipment and telehealth. Conclusions: COVID-19 was associated with a significant and abrupt reduction in cardiovascular diagnostic testing across the globe, especially affecting the world's economically challenged. Further study of cardiovascular outcomes and COVID-19–related changes in care delivery is warranted
Impact of COVID-19 on Diagnostic Cardiac Procedural Volume in Oceania: The IAEA Non-Invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID)
Objectives: The INCAPS COVID Oceania study aimed to assess the impact caused by the COVID-19 pandemic on cardiac procedure volume provided in the Oceania region. Methods: A retrospective survey was performed comparing procedure volumes within March 2019 (pre-COVID-19) with April 2020 (during first wave of COVID-19 pandemic). Sixty-three (63) health care facilities within Oceania that perform cardiac diagnostic procedures were surveyed, including a mixture of metropolitan and regional, hospital and outpatient, public and private sites, and 846 facilities outside of Oceania. The percentage change in procedure volume was measured between March 2019 and April 2020, compared by test type and by facility. Results: In Oceania, the total cardiac diagnostic procedure volume was reduced by 52.2% from March 2019 to April 2020, compared to a reduction of 75.9% seen in the rest of the world (p<0.001). Within Oceania sites, this reduction varied significantly between procedure types, but not between types of health care facility. All procedure types (other than stress cardiac magnetic resonance [CMR] and positron emission tomography [PET]) saw significant reductions in volume over this time period (p<0.001). In Oceania, transthoracic echocardiography (TTE) decreased by 51.6%, transoesophageal echocardiography (TOE) by 74.0%, and stress tests by 65% overall, which was more pronounced for stress electrocardiograph (ECG) (81.8%) and stress echocardiography (76.7%) compared to stress single-photon emission computerised tomography (SPECT) (44.3%). Invasive coronary angiography decreased by 36.7% in Oceania. Conclusion: A significant reduction in cardiac diagnostic procedure volume was seen across all facility types in Oceania and was likely a function of recommendations from cardiac societies and directives from government to minimise spread of COVID-19 amongst patients and staff. Longer term evaluation is important to assess for negative patient outcomes which may relate to deferral of usual models of care within cardiology